{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:22:26Z","timestamp":1793733746373,"version":"4.6.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773968"],"award-info":[{"award-number":["81773968"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Otolaryngology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.amjoto.2021.103148","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T03:15:32Z","timestamp":1624677332000},"page":"103148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Reliability and toxicity of bevacizumab for neurofibromatosis type 2-related vestibular schwannomas: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"42","author":[{"given":"Jianwei","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxin","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yansong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjoto.2021.103148_bb0005","first-page":"826","article-title":"A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor","volume":"75","author":"Trofatter","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.amjoto.2021.103148_bb0010","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/jnnp-2018-318538","article-title":"Schwannomatosis: a genetic and epidemiological study","volume":"89","author":"Evans","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.amjoto.2021.103148_bb0015","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1097\/00006123-199605000-00004","article-title":"The neuroimaging and clinical spectrum of neurofibromatosis 2","volume":"38","author":"Mautner","year":"1996","journal-title":"Neurosurgery"},{"key":"10.1016\/j.amjoto.2021.103148_bb0020","first-page":"92","article-title":"Neurofibromatosis 2 in the pediatric age group","volume":"33","author":"Mautner","year":"1993","journal-title":"Neurosurgery"},{"key":"10.1016\/j.amjoto.2021.103148_bb0025","first-page":"603","article-title":"A clinical study of type 2 neurofibromatosis","volume":"84","author":"Evans","year":"1992","journal-title":"Q J Med"},{"key":"10.1016\/j.amjoto.2021.103148_bb0030","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3171\/jns.1994.80.3.0541","article-title":"Interface between the facial nerve and large acoustic neurinomas. Immunohistochemical study of the cleavage plane in NF2 and non-NF2 cases","volume":"80","author":"Jaaskelainen","year":"1994","journal-title":"J Neurosurg"},{"key":"10.1016\/j.amjoto.2021.103148_bb0035","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3109\/00016489.2015.1040170","article-title":"Staged resection for vestibular schwannoma","volume":"135","author":"Kunimoto","year":"2015","journal-title":"Acta Otolaryngol"},{"issue":"9679","key":"10.1016\/j.amjoto.2021.103148_bb0040","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/S0140-6736(09)60259-2","article-title":"Neurofibromatosis type 2","volume":"373","author":"Asthagiri","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.amjoto.2021.103148_bb0045","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"Plotkin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjoto.2021.103148_bb0050","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/neuonc\/noz153","article-title":"EANO guideline on the diagnosis and treatment of vestibular schwannoma","volume":"22","author":"Goldbrunner","year":"2020","journal-title":"Neuro-Oncology"},{"issue":"8","key":"10.1016\/j.amjoto.2021.103148_bb0055","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3390\/jcm9082664","article-title":"Factors associated with adverse cardiovascular events in cancer patients treated with bevacizumab","volume":"9","author":"Ngo","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.amjoto.2021.103148_bb0060","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11060-019-03234-8","article-title":"Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes","volume":"144","author":"Lu","year":"2019","journal-title":"J Neurooncol"},{"key":"10.1016\/j.amjoto.2021.103148_bb0065","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.amjoto.2021.103148_bb0070","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","article-title":"Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients","volume":"33","author":"Plotkin","year":"2012","journal-title":"Otol Neurotol"},{"issue":"2","key":"10.1016\/j.amjoto.2021.103148_bb0075","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11060-015-1828-8","article-title":"Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2","volume":"124","author":"Hochart","year":"2015","journal-title":"J Neuro-oncol"},{"issue":"5","key":"10.1016\/j.amjoto.2021.103148_bb0080","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/pbc.28228","article-title":"Bevacizumab for NF2-related vestibular schwannomas of childhood and adolescence","volume":"67","author":"Renzi","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"10.1016\/j.amjoto.2021.103148_bb0085","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.3390\/cancers11121862","article-title":"Minimal effect of Bevacizumab treatment on residual vestibular Schwannomas after partial resection in young neurofibromatosis type 2 patients","volume":"11","author":"Gugel","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.amjoto.2021.103148_bb0090","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/lary.28998","article-title":"Current management of large vestibular schwannomas for NF2 patients in a national reference center","volume":"131","author":"Comes","year":"2021","journal-title":"Laryngoscope"},{"issue":"12","key":"10.1016\/j.amjoto.2021.103148_bb0095","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1007\/s00405-015-3604-y","article-title":"Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2","volume":"272","author":"Farschtschi","year":"2015","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"5","key":"10.1016\/j.amjoto.2021.103148_bb0100","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.neuchi.2016.09.004","article-title":"Medical treatment in neurofibromatosis type 2. Review of the literature and presentation of clinical reports","volume":"64","author":"Goutagny","year":"2018","journal-title":"Neurochirurgie"},{"issue":"5","key":"10.1016\/j.amjoto.2021.103148_bb0105","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1055\/s-0038-1676628","article-title":"Long-term effects of bevacizumab on vestibular schwannoma volume in neurofibromatosis type 2 patients","volume":"80","author":"Killeen","year":"2019","journal-title":"J Neurol Surg B Skull Base"},{"key":"10.1016\/j.amjoto.2021.103148_bb0110","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1007\/s00405-014-3398-3","article-title":"The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2","volume":"272","author":"Alanin","year":"2015","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"14","key":"10.1016\/j.amjoto.2021.103148_bb0115","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1200\/JCO.2015.64.3817","article-title":"Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-related vestibular schwannomas","volume":"34","author":"Blakeley","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.amjoto.2021.103148_bb0120","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/nop\/npv065","article-title":"Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation","volume":"3","author":"Morris","year":"2016","journal-title":"Neuro-oncol Pract"},{"key":"10.1016\/j.amjoto.2021.103148_bb0125","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1200\/JCO.19.01367","article-title":"Multicenter, prospective, phase II and biomarker study of high-dose bevacizumab as induction therapy in patients with neurofibromatosis type 2 and progressive vestibular schwannoma","volume":"37","author":"Plotkin","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.amjoto.2021.103148_bb0130","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1177\/0194599818809085","article-title":"Bevacizumab for hearing preservation in neurofibromatosis type 2: emphasis on patient-reported outcomes and toxicities","volume":"160","author":"Sverak","year":"2019","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.amjoto.2021.103148_bb0135","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/02688690500305399","article-title":"Vestibular schwannoma management: what is the \u2018best\u2019 option?","volume":"19","author":"Rutherford","year":"2005","journal-title":"Br J Neurosurg"},{"key":"10.1016\/j.amjoto.2021.103148_bb0140","doi-asserted-by":"crossref","first-page":"176","DOI":"10.2176\/nmc.46.176","article-title":"Optimal extent of resection in vestibular schwannoma surgery: relationship to recurrence and facial nerve preservation","volume":"46","author":"Seol","year":"2006","journal-title":"Neurol Med Chir"},{"key":"10.1016\/j.amjoto.2021.103148_bb0145","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/02688697.2013.861386","article-title":"Review of radiation therapy services for neurofibromatosis (NF2) patients in England","volume":"28","author":"Gilkes","year":"2014","journal-title":"Br J Neurosurg"}],"container-title":["American Journal of Otolaryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196070921002490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196070921002490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T05:08:40Z","timestamp":1759295320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196070921002490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0196070921002490"],"URL":"https:\/\/doi.org\/10.1016\/j.amjoto.2021.103148","relation":{},"ISSN":["0196-0709"],"issn-type":[{"value":"0196-0709","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reliability and toxicity of bevacizumab for neurofibromatosis type 2-related vestibular schwannomas: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Otolaryngology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjoto.2021.103148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103148"}}